Sequential recovery masks 14% YoY revenue decline; H2 guidance untested

Q2 ₹476.6 Cr up 12.9% from Q1, but YoY down 14.2% vs prior year

Q2 missed YoY; requires sharp H2 rebound to meet prior guidance. Unproven.

Reported OPM 7.4%, NPM 0.5% well below 9.2% standalone guidance. Margin compression despite EBITDA gains.

Pharma CDMO down 27% YoY in Q2. Three contracts have 18–36 month lead times; not near-term revenue drivers.

Two ADC GMP campaigns completed Q2; inventory destocking ongoing. Progress real but early-stage; no revenue contribution yet.

Prior call (Q1): 'H2 will return to YoY growth.' Q2 delivered -14.2% YoY, forcing H2 to overcome a deeper trough. No upward revision to FY27 target; maintained but less credible given Q2 miss.

Prior 9.2% standalone margin guidance not re-affirmed; management now says only 'sequential improvement' with no timeline or level. This is a de facto downgrade from prior specificity.

New revenue drivers, but 18–36 month lead times push material upside into FY28–FY29, not H2 FY27. Does not offset near-term headwinds.

Prior ₹3B FY27 capex target being tracked. H1 ₹1B deployed; H2 needs ~₹2B to hit full-year target. Management says 'H2 stronger' but no specific quantum.

Facility closure order issued; management claim that 'we are not providing that level of clarity' on revenue impact. Signals execution risk and near-term uncertainty not pre-disclosed.

Two are from large pharma innovators, patent-protected, both smallmolecule. Lead time 18–36 months before ramp. Yann: 'uncertainty from customers on how forecast will develop moving forward.'

Yann: 'Two of our small molecule KSMs are essentially becoming generics…volume has gone down…will continue as well for the foreseeable future.' Restocking ongoing but timelines unclear.

Umang: 'Inspections are over…We do not know what the FDA classification is as of this time, but we are hoping to hear over the next one month to 45 days…At this point, we are not seeing any impact.'

Yann: 'We have good relation with several large pharmaceutical customers…confirmed during CPHI meeting…large pharmaceutical customers have trusted Cohance on their commercial products to be their supplier.'

Umang: 'Half-year-on-half performance will be improving…Specific guidance, we are not providing. All we are saying is sequential, business will improve.' Declined to quantify.

Umang: 'We are not providing that level of guidance because we are assessing the impact…this is also a plant which is non-GMP…not our largest plant.' Declined specificity on impact magnitude.

Prior call (Q1) stated; reaffirmed in Q2. Q2 missed YoY (-14.2%), so H2 must overcome deeper trough. Sequenial trajectory positive but YoY bar high.

Mgmt: 'All we are saying is sequential, business will improve. Specific guidance, we are not providing.' Reflects uncertainty on timing and magnitude of margin recovery.

H1 deployed ₹1B; H2 expected stronger. On track if H2 ≈ ₹2B. Strategic focus: adjacent capabilities in ADC platform and R&D infrastructure.

Three API facilities under USFDA inspection; classification decision pending within 1–3 months. If adverse, could limit revenue-generating capacity in H2 FY27.

Suryapet facility (non-GMP, smaller plant) closure order in place for undefined period. Management evasive on revenue impact; timelines for remediation and reopening unspecified. Creates execution and earnings uncertainty.

Pharma CDMO business declined -27% in Q2, -32% in H1 YoY. Management attributes to inventory correction and cites two established commercial programs as source. Risk: destocking may extend into FY28 if customer demand remains weak or if additional CDMO programs enter correction cycles.

Q2 delivered OPM 7.4%, NPM 0.5%, vs. 9.2% standalone guidance. Management declined to quantify margin recovery path, stating only 'sequential improvement.' Risk: if raw material inflation persists or CDMO destocking deepens, margins could remain compressed longer than implied.

Three significant commercial programs from large pharma innovators secured in Q2. However, lead times span 18–36 months before revenue ramp. Risk: delays in customer R&D, regulatory milestones, or manufacturing validation could push revenue contribution further out, delaying margin improvement and FY28+ targets.

Specialty Chemicals segment (Agrochemical CDMO, crop protection) down 40.6% YoY in Q2. Driven by lower CDMO volumes, pricing pressure, and legacy product generics. Risk: if agricultural markets remain soft or if pricing power erodes further, this segment may not recover to prior-year levels in FY27.